key: cord-0804777-hg0kk6qu
authors: Hasan Ahmad, Syed; Smith, Richard; Camilleri, Brian
title: Belatacept, kidney transplantation and COVID‐19: successful management of the first reported case within the United Kingdom
date: 2020-06-30
journal: Clin Transplant
DOI: 10.1111/ctr.14026
sha: 7a5c3c12dd992fe5390e6f3d7bbbb849ed9b5b6d
doc_id: 804777
cord_uid: hg0kk6qu

Kidney transplant recipients may be at particular risk of acquiring SARS‐CoV‐2 infection with poor outcomes.(1) In a recent case report (2) it was hypothesised that kidney transplant recipients on maintenance belatacept, a cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) fusion protein, have a milder disease course due to belatacept mitigating the cytokine storm and resultant acute respiratory distress syndrome which have been linked to severity of COVID‐19. (3) Here we present the first reported case in the United Kingdom of a kidney transplant patient on belatacept who on the contrary developed a severe COVID‐19 pneumonia requiring intensive care admission and intubation.

Kidney transplant recipients may be at particular risk of acquiring SARS-CoV-2 infection with poor outcomes. 1 In a recent case report 2 

British Transplant Society guidelines 4 and prednisolone was increased to 20 mg once a day.

Two serial SARS-Cov-2 reverse-transcriptase polymerase chain reaction (RT-PCR) swabs came back positive and the laboratory parameters and chest x-ray were also suggestive of COVID-19 (table 1, figure 1 ). The clinical condition started to deteriorate, and he required intubation in intensive care for four days. Other complications were a superadded bacterial pneumonia, urinary tract infection requiring antibiotics and a resolving acute kidney injury that did not require biopsy.

After transfer from intensive care to the ward, MMF was restarted and he was discharged after a negative repeat SARS-CoV-2 RT-PCR ( Figure 2 ).

The belatacept infusion was restarted on the 7 th May and he is currently doing well and is being closely monitored as an outpatient (Figure 2 ).

immune responses. Drugs that prevent rejection may therefore also impair anti-viral responses. The immune response to SARS-CoV-2 appears to be a typical anti-viral immune response 5,6 and we suggest that avoidance of belatacept until viral clearance has been achieved is likely to be safest strategy. In our patient the clinical course was severe and unlike the case reported by Marx 

No conflict of interest to declare.

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. 

This article is protected by copyright. All rights reserved 

COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter

First case of COVID-19 in a kidney transplant recipient treated with belatacept

The pathogenesis and treatment of the 'Cytokine Storm'' in COVID-19

All authors contributed equally in all aspects of preparation of this manuscript.